PARP inhibitors are currently in clinical trial for PDA (ClinicalTrials.gov identifiers: NCT00515866, NCT01286987, NCT00047307, NCT01989546, NCT02042378) (123, 133). Here, PARP1 is linked to Patent ductus arteriosus.